Chartwell Investment Partners LLC lessened its holdings in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 43.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,147 shares of the life sciences company’s stock after selling 39,478 shares during the period. Chartwell Investment Partners LLC owned approximately 0.07% of Integra Lifesciences worth $2,448,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also modified their holdings of the company. Whittier Trust Co. acquired a new stake in Integra Lifesciences during the third quarter valued at $169,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Integra Lifesciences by 38.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,806 shares of the life sciences company’s stock valued at $182,000 after buying an additional 1,054 shares during the period. Zions Bancorporation acquired a new stake in Integra Lifesciences during the third quarter valued at $205,000. Quantitative Systematic Strategies LLC acquired a new stake in Integra Lifesciences during the third quarter valued at $264,000. Finally, Ameritas Investment Partners Inc. grew its position in Integra Lifesciences by 3.6% during the second quarter. Ameritas Investment Partners Inc. now owns 5,409 shares of the life sciences company’s stock valued at $295,000 after buying an additional 187 shares during the period. 90.93% of the stock is owned by hedge funds and other institutional investors.
Shares of Integra Lifesciences Holdings Corp (NASDAQ IART) traded down $0.09 during midday trading on Wednesday, hitting $56.14. 525,979 shares of the stock traded hands, compared to its average volume of 517,422. The firm has a market capitalization of $4,377.62, a price-to-earnings ratio of 68.46, a price-to-earnings-growth ratio of 1.72 and a beta of 0.65. Integra Lifesciences Holdings Corp has a 1-year low of $40.51 and a 1-year high of $57.14. The company has a current ratio of 2.36, a quick ratio of 1.51 and a debt-to-equity ratio of 1.85.
In related news, VP Joseph Vinhais sold 6,800 shares of the business’s stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $54.13, for a total transaction of $368,084.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Richard E. Caruso sold 32,880 shares of the business’s stock in a transaction dated Thursday, March 8th. The stock was sold at an average price of $53.68, for a total transaction of $1,764,998.40. The disclosure for this sale can be found here. Insiders have sold 70,996 shares of company stock worth $3,822,267 over the last 90 days. 21.50% of the stock is currently owned by company insiders.
Several analysts recently commented on the stock. Oppenheimer restated a “buy” rating on shares of Integra Lifesciences in a research report on Thursday, January 11th. JMP Securities raised their price target on shares of Integra Lifesciences from $57.00 to $60.00 and gave the company a “market outperform” rating in a research report on Wednesday, February 28th. Jefferies Group restated a “buy” rating and set a $63.00 price target on shares of Integra Lifesciences in a research report on Thursday, March 1st. TheStreet upgraded shares of Integra Lifesciences from a “c+” rating to a “b-” rating in a research report on Wednesday, February 7th. Finally, BidaskClub upgraded shares of Integra Lifesciences from a “strong sell” rating to a “sell” rating in a research report on Monday, February 5th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $54.18.
TRADEMARK VIOLATION NOTICE: This news story was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://stocknewstimes.com/2018/03/14/integra-lifesciences-holdings-corp-iart-position-cut-by-chartwell-investment-partners-llc.html.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.